Accuray announces positive results from phase II trial of CyberKnife System in prostate cancer patients

Accuray Incorporated has announced data from a prospective, phase II, 17-centre study which showed that treatment with the CyberKnife System for low- and intermediate-risk prostate cancer provides excellent long-term results. At five years, the disease-free survival rate for low-risk prostate cancer patients was 100 percent and for intermediate-risk patients was 88.5 percent. The study was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium.